SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare inches up on getting EIR from USFDA for Raichur API manufacturing site

20 Apr 2020 Evaluate

Shilpa Medicare is currently trading at Rs. 379.80, up by 0.85 points or 0.22% from its previous closing of Rs. 378.95 on the BSE.

The scrip opened at Rs. 395.00 and has touched a high and low of Rs. 397.85 and Rs. 377.00 respectively. So far 1095 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 538.75 on 26-Feb-2020 and a 52 week low of Rs. 190.80 on 04-Sep-2019.

Last one week high and low of the scrip stood at Rs. 397.85 and Rs. 327.45 respectively. The current market cap of the company is Rs. 3089.46 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 26.89% and 19.31% respectively.

Shilpa Medicare has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between February 03 and February 07 2020. The USFDA has determined that the inspection classification of this facility is No Action Indicated (NAI).

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications


Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×